Publications - DC
T cell adoptive immunity for cancer | Gene-modified T cells for HIV | Dendritic cell vaccines for cancer | Reviews
| Publication |
PMID |
PMCID |
| Fesnak AD, Hanley PJ, Levine BL. Considerations in T Cell Therapy Product Development for B CellLeukemia and Lymphoma Immunotherapy. Curr Hematol Malig Rep. 2017 Jul 31;1-9. doi: 10.1007/s11899-017-0395-9. PDF. Review. |
|
|
| Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev.2016 Dec 31;4:92-101. doi: 10.1016/j.omtm.2016.12.006. eCollection 2017 Mar 17. Review. |
28344995 |
PMC5363291 |
| Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016 Aug 23;16(9):566-81. DOI: 10.1038/nrc.2016.97. Review. |
27550819 |
|
| Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev. 2016 Jul;30(3):139-45. doi: 10.1016/j.tmrv.2016.03.001. Epub 2016 Mar 28. |
27067907 |
PMC4914456 |
| Maus MV, Levine BL. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.Oncologist.2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23. Review. |
27009942 |
PMC4861363 |
| June CH, Levine BL. T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140374. doi: 10.1098/rstb.2014.0374. Review. |
26416683 |
PMC4634001 |
| Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015 Mar;22(2):79-84. DOI: 10.1038/cgt.2015.5. Epub 2015 Feb 13. Review. |
25675873 |
|
| June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014 Sep;63(9):969-75. DOI: 10.1007/s00262-014-1568-1. Epub 2014 Jun 19. Review. |
24943274 |
PMC4142345 |
| Melenhorst JJ, Levine BL. Innovation and opportunity for chimeric antigen receptor targeted T cells. Cytotherapy. 2013 Sep;15(9):1046-53. DOI: 10.1016/j.jcyt.2013.02.007. Epub 2013 Apr 2. Review. |
23562306 |
|
| Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ Jr, Levine BL, Carroll RG, Riley JL, June CH. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res. 2008;42(1-3):182-96. DOI: 10.1007/s12026-008-8070-9. Review. |
18949448 |
PMC3809041 |
| Powell DJ, Levine BL. Adoptive T-cell therapy for malignant disorders. Haematologica. 2008 Oct;93(10):1452-6. DOI: 10.3324/haematol.13717. |
18827263 |
|
| Levine, BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther. 2008 Apr;8(4):475-89. DOI: 10.1517/14712598.8.4.475. |
18352851 |
|
| Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, Macgregor RR, June CH, Dropulic B. Regulatory Considerations for Novel Gene Therapy Products: A Review of the Process Leading to the First Clinical Lentiviral Vector. Hum Gene Ther. 2005 Jan;16(1):17-25. DOI: 10.1089/hum.2005.16.17. Review. |
15703485 |
